Lewy Body Dementia

Lewy Body Dementia
Lewy Body Dementia
Compare differential diagnostic features of neurocognitive disorders (Lewy Body Dement
· Explain the evidenced-based psychotherapy and psychopharmacologic treatment for your assigned neurocognitive disorder. (Lewy Body Dementia)
· Evaluate benefits and risks of neurocognitive therapies
· Identify the risks of different types of therapy and explain how the benefits of the therapy that might be achieved might outweigh the risks.
· Support your rationale with references to the Learning Resources or other academic resource (REFERENCES MUST BE LESS THAN 5 YEARS OLD)
PLEASE YOU MUST INCLUDE INTRODUCTION, CONCLUSION AND REFERENCES
Learning Resources
Required Readings
Sadock, B. J., Sadock, V. A., & Ruiz, P. (2014). Kaplan & Sadock’s synopsis of psychiatry: Behavioral sciences/clinical psychiatry (11th ed.). Philadelphia, PA: Wolters Kluwer.
· Chapter 21, “Neurocognitive Disorders” (pp. 694–741)
Gabbard, G. O. (2014). Gabbard’s treatment of psychiatric disorders (5th ed.). Washington, DC: American Psychiatric Publications.
· Chapter 63, “Delirium”
· Chapter 64, “Neurocognitive Disorder Due to Alzheimer’s Disease”
· Chapter 65, “Frontotemporal Neurocognitive Disorder”
· Chapter 66, “Vascular Neurocognitive Disorder”
· Chapter 67, “Neurocognitive Disorder Due to Parkinson’s Disease”
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.
· “Neurocognitive Disorders”
Stahl, S. M. (2014). Prescriber’s Guide: Stahl’s Essential Psychopharmacology (5th ed.). New York, NY: Cambridge University Press.
To access information on specific medications, click on The Prescriber’s Guide, 5th Ed. tab on the Stahl Online website and select the appropriate medication.
Alzheimer disease Delirium Dementia Parkinson’s disease dementia
caprylidene donepezil galantamine memantine rivastigmine haloperidol (adjunct) lorazepam (adjunct) donepezil galantamine memantine rivastigmine rivastigmine pimavanserin
Note: For more information on Pimavanserin, see:
Acadia Pharmaceuticals. (2017). Transform the treatment of Parkinson’s disease psychosis with NUPLAZID. Retrieved from https://www.nuplazidhcp.com/?gclid=CIHS5auvwtMCFQkaaQodrU0FGQ
U.S. Food and Drug Administration. (n. d.). Highlights of prescribing information: Nuplazid. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf
Hopkins, S. A., & Chan, D. (2016). Key emerging issues in frontotemporal dementia. Journal of Neurology, 263(2), 407–413. doi:10.1007/s00415-015-7880-7
Walker, Z., Possin, K. L., Boeve, B. F., & Aarsland, D. (2017). Lewy body dementias. Focus, 15(1), 85–100. doi: 10.1176/appi.focus.15105
Required Media
Laureate Education (Producer). (2017a). A gentleman with a neurocognitive disorder [Multimedia file]. Baltimore, MD: Author.
Bolin, P. (2015, December 31). Neurocognitive disorders – CRASH! Medical review series [Video file]. Retrieved from https://www.youtube.com/watch?v=bQXOPITY9XM
Optional Resources
Kota, L. N., Bharath, S., Purushottam, M., Moily, N. S., Sivakumar, P. T., Varghese, M., . . . Jain, S. (2015). Reduced telomere length in neurodegenerative disorders may suggest shared biology. The Journal of Neuropsychiatry and Clinical Neurosciences, 27(2), e92–e96. doi:10.1176/appi.neuropsych.13100240
Lepkowsky, C. M. (2016). Neurocognitive disorder with Lewy bodies: Evidence-based diagnosis and treatment. Practice Innovations, 1(4), 234–242. doi:10.1037/pri0000031
Oltra-Cucarella, J., Pérez-Elvira, R., Espert, R., & Sohn McCormick, A. (2016). Are cognitive interventions effective in Alzheimer’s disease? A controlled meta-analysis of the effects of bias. Neuropsychology, 30(5), 631–652. doi:10.1037/neu0000283